MA48870A - Anticorps anti-sortiline et leurs méthodes d'utilisation - Google Patents

Anticorps anti-sortiline et leurs méthodes d'utilisation

Info

Publication number
MA48870A
MA48870A MA048870A MA48870A MA48870A MA 48870 A MA48870 A MA 48870A MA 048870 A MA048870 A MA 048870A MA 48870 A MA48870 A MA 48870A MA 48870 A MA48870 A MA 48870A
Authority
MA
Morocco
Prior art keywords
sortiline
antibodies
methods
sortiline antibodies
Prior art date
Application number
MA048870A
Other languages
English (en)
Other versions
MA48870B1 (fr
Inventor
Anthony B Cooper
Michael Kurnellas
Robert Pejchal
Arnon Rosenthal
Tina Schwabe
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Priority claimed from PCT/US2019/041614 external-priority patent/WO2020014617A1/fr
Publication of MA48870A publication Critical patent/MA48870A/fr
Publication of MA48870B1 publication Critical patent/MA48870B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA48870A 2018-07-13 2019-07-12 Anticorps anti-sortiline et leurs méthodes d'utilisation MA48870B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862698007P 2018-07-13 2018-07-13
PCT/US2019/041614 WO2020014617A1 (fr) 2018-07-13 2019-07-12 Anticorps anti-sortiline et leurs méthodes d'utilisation

Publications (2)

Publication Number Publication Date
MA48870A true MA48870A (fr) 2020-04-01
MA48870B1 MA48870B1 (fr) 2023-03-31

Family

ID=83218695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48870A MA48870B1 (fr) 2018-07-13 2019-07-12 Anticorps anti-sortiline et leurs méthodes d'utilisation

Country Status (2)

Country Link
AR (1) AR122237A1 (fr)
MA (1) MA48870B1 (fr)

Also Published As

Publication number Publication date
AR122237A1 (es) 2022-08-31
MA48870B1 (fr) 2023-03-31

Similar Documents

Publication Publication Date Title
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
EP3917564A4 (fr) Anticorps anti-claudine 18 et leurs méthodes d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
EP3820496A4 (fr) Constructions de fusion et leurs méthodes d'utilisation
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d'utilisation
MA53492A (fr) Anticorps anti-cd33 et leurs méthodes d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
EP3728323A4 (fr) Anticorps anti-fzd et méthodes d'utilisation
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
MA48462A (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP4004051A4 (fr) Anticorps immunomodulateurs et leurs méthodes d'utilisation
MA50958A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
EP3743109A4 (fr) Anticorps anti-mica/b et leurs méthodes d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
MA52014A (fr) Anticorps anti-klk5 et méthodes d'utilisation
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA45602A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3684369A4 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie